<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saugi Abduh</style></author><author><style face="normal" font="default" size="100%">Purwanto Bambang</style></author><author><style face="normal" font="default" size="100%">Dirgahayu Paramasari</style></author><author><style face="normal" font="default" size="100%">Soetrisno</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardioprotective Effects of Thymoquinone on Myocardial Fibrosis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cardiac Fibrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Lipopolysaccharide</style></keyword><keyword><style  face="normal" font="default" size="100%">Nigella sativa</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">924-927</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Thymoquinone (TQ) is one of the active ingredients in herbal plants such as &lt;em&gt;Nigella sativa &lt;/em&gt;which has antioxidant and anti-inflammatory properties thus may inhibits cardiac fibrosis formation. This study aims to determine the effectiveness of Thymoquinone as a cardioprotective agent in suppressing the extent of fibrosis in Wistar rats induced with lipopolysaccharide (LPS). &lt;strong&gt;Methods&lt;/strong&gt;: This post-test only control study used 30 Wistar rats which were divided into 5 groups: saline, LPS-induced cardiac fibrosis, LPS-induced cardiac fibrosis treated with TQ 10 mg/mL, LPS-induced cardiac fibrosis treated with TQ 20 mg/mL, and LPS-induced cardiac fibrosis treated with TQ 40 mg/mL. Serum IL-6, GSH, and cTnT levels were measured using ELISA, and Mason's trichrome staining was used to assess myocardial fibrosis. &lt;strong&gt;Results:&lt;/strong&gt; The LPS10+TQ20 and LPS10+TQ40 groups exhibited significantly lower levels of IL-6 compared to the LPS10+TQ10 group (p &amp;lt; 0.05). GSH levels did not show a significant decrease in the TQ groups across different doses (p=0.771). The TQ-treated group demonstrated lower cTnT levels compared to the LPS-only group (p&amp;lt;0.05). Thymoquinone treatment resulted in reduced fibrosis area compared to the LPS10 group (p&amp;lt;0.05). &lt;strong&gt;Conclusions: &lt;/strong&gt;TQ has a promising cardioprotective effect on the formation of cardiac fibrosis in Wistar rats induced with LPS.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">924</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Saugi Abduh&lt;sup&gt;1,2,*&lt;/sup&gt;, Purwanto Bambang&lt;sup&gt;3&lt;/sup&gt;, Dirgahayu Paramasari&lt;sup&gt;4&lt;/sup&gt;, Soetrisno&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Student in Medical Science, Faculty of Medicine, Sebelas Maret University, Surakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Division of Cardiology, Department of Internal Medicine, Sultan Agung Islamic University, Semarang, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Nephrology and Hypertension, Department of Internal Medicine, Sebelas Maret University, Surakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Parasitology, Sebelas Maret University, Surakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Obstetrics and Gynecology, Sebelas Maret University, Surakarta, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>